Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
ICR scientists unveil AI-powered platform that helps researchers speed up biomarker discoveries for personalised cancer treatment
An ICR team has unveiled a cutting-edge research platform powered by artificial intelligence (AI) that will revolutionise cancer research by allowing researchers to integrate and analyse large and complex clinical trial datasets, speeding up the discovery of new cancer biomarkers.
New study confirms hormone’s role in post-menopausal breast cancer risk
In the largest and most comprehensive study of its kind, researchers have provided further evidence that a hormone responsible for regulating breast development acts as a risk factor for breast cancer in post-menopausal women.
£5.5m research funding to transform bowel cancer care
Scientists from The Institute of Cancer Research, London, are part of a team of international researchers who have secured £5.5million in funding to find smarter, kinder treatments for people living with bowel cancer.
-carousel-945x581.jpg?sfvrsn=d29fb9e9_2 "A high magnification image of ovarian clear cell carcinoma (photo: Nephron) carousel 945x581")
Newly identified biomarker could improve treatment for people with rare type of ovarian cancer
Scientists at The Institute of Cancer Research, London, have identified a gene that affects how ovarian clear cell carcinoma (OCCC) could respond to a new class of drug called ATR inhibitors.